Matthew D. Hellmann, MD, on SCLC: Results From CheckMate 032

2017 ASCO Annual Meeting
Tweet this page

Matthew D. Hellmann, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)

Advertisement

Advertisement



Advertisement